Tinlarebant is the first therapeutic candidate to demonstrate clinical efficacy in Stargardt disease, having met the primary endpoint, reductions in lesion growth rate, in the pivotal, global Phase 3 ...
Tinlarebant is the first therapeutic candidate to demonstrate clinical efficacy in Stargardt disease, having met the primary ...
Latitude Investment Management, an investment management firm, released its fourth-quarter 2025 investor letter. A copy of ...
Key highlights from the first quarter of operations under the expanded management team include the following:Anticipated FDA decision on the ...
FDA Breakthrough Designation -- CardiAMP Cell Therapy for ischemic heart failure holds FDA breakthrough status and is ...
Key highlights from the first quarter of operations under the expanded management team include the following: Anticipated FDA decision on the Company's ANDA for Preservative-Free Ketamine in Q3 2026 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results